期刊文献+

家族性高胆固醇血症合并极高危ASCVD 1例 被引量:1

A case of familial hypercholesterolemia with very high-risk ASCVD
原文传递
导出
摘要 本研究报道了1例29岁男性家族性高胆固醇血症(FH)患者,血浆低密度脂蛋白胆固醇(LDL-C)异常升高、合并黄色瘤且早发冠心病。遗传学分析显示该患者发生了低密度脂蛋白受体(LDLR)编码基因的复合杂合突变,属一种极其罕见的基因突变类型,该变异导致LDLR自身表达、摄取及结合LDL-C功能受损,使前蛋白转化酶枯草溶菌素9型(PCSK9)抑制剂效果不佳。基于遗传学诊断,个体化的给予患者PCSK9抑制剂、最大可耐受剂量他汀和依折麦布,并成功接受了冠状动脉介入治疗。 This study report a 29-year-old male diagnosed with familial hypercholesterolemia,elevated low-density lipoprotein cholesterol(LDL-C),xanthomas,and premature coronary heart disease.Genetic analysis revealed that this patient had a compound heterozygous mutated gene encoding the low-density lipoprotein receptor(LDLR).This rare genetic mutation can impaire LDLR expression,uptake,and LDL-C binding function,making pre-protein converting enzyme subtilisin 9(PCSK9)inhibitors less effective.Based on genetic diagnosis,this patient received individualized treatment with PCSK9 inhibitor,a maximum tolerated dose of statin and ezetimibe,and successfully underwent coronary intervention.
作者 李云云 折剑青 罗玲 王燕妮 霍建华 任洁 LI Yunyun;ZHE Jianqing;LUO Ling;WANG Yanni;HUO Jianhua;REN Jie(Department of Cardiology,First Affliated Hospital,School of Medicine of Xi’an Jiao Tong University,Xi'an,710061,China;Department of Cardiology,Xi′an XD Group Hospital)
出处 《临床心血管病杂志》 CAS 北大核心 2022年第6期513-516,共4页 Journal of Clinical Cardiology
关键词 家族性高胆固醇血症 动脉粥样硬化 familial hypercholesterolemia atherosclerosis
  • 相关文献

参考文献2

二级参考文献37

  • 1JACOBSON T A,ITO M K,MAKI K C,et al.National lipid association recommendations for patientcentered management of dyslipidemia:part 1-full report[J].J Clin Lipidol,2015,9:129-169.
  • 2ABIFADEL M,VARRET M,RABES J P,et al.Mutations in PCSK9cause autosomal dominant hypercholesterolemia[J].Nat Genet,2003,34:154-156.
  • 3NICHOLLS S J,BRANDRUP-WOGNSEN G,PALMER M,et al.Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids(from VOYAGER)[J].Am J Cardiol,2010,105:69-76.
  • 4PANDOR A,ARA R M,TUMUR I,et al.Ezetimibe monotherapy for cholesterol lowering in 2,722people:systematic review and meta-analysis of randomized controlled trials[J].J Intern Med,2009,265:568
  • 5KOREN M J,SCOTT R,KIM J B,et al.Efficacy,safety,and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9as monotherapy in patients with hypercholesterolaemia(MENDEL):a randomised,double-blind,placebo-controlled,phase 2study[J].Lancet,2012,380:1995-2006.
  • 6KOREN M J,LUNDQVIST P,BOLOGNESE M,et al.Anti-PCSK9 monotherapy for hypercholesterolemia:the MENDEL-2randomized,controlled phaseⅢclinical trial of evolocumab[J].J Am Coll Cardiol,2014,63:2531-2540.
  • 7SULLIVAN D,OLSSON A G,SCOTT R,et al.Effect of a monoclonal antibody to PCSK9on low-density lipoprotein cholesterol levels in statin-intolerant patients:the GAUSS randomized trial[J].JAMA,2012,308:2497-2506.
  • 8STROES E,COLQUHOUN D,SULLIVAN D,et al.Anti-PCSK9antibody effectively lowers cholesterol in patients with statin intolerance:the GAUSS-2 randomized,placebo-controlled phase 3clinical trial of evolocumab[J].J Am Coll Cardiol,2014,63:2541-2548.
  • 9NISSEN S E,STROES E,DENT-ACOSTA R E,et al.Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance:The GAUSS-3Randomized Clinical Trial[J].JAMA,2016,315:1580-1590.
  • 10ROTH E M,MCKENNEY J M.ODYSSEY MONO:effect of alirocumab 75 mg subcutaneously every 2weeks as monotherapy versus ezetimibe over 24weeks[J].Future Cardiol,2015,11:27-37.

共引文献10

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部